Patents Assigned to Teva Women's Health, Inc.
  • Patent number: 9220692
    Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: December 29, 2015
    Assignee: TEVA WOMEN'S HEALTH, INC.
    Inventors: Charles E. DiLiberti, Anu Mahashabde
  • Patent number: 8980304
    Abstract: The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b) an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: March 17, 2015
    Assignee: Teva Women's Health, Inc.
    Inventor: Jiaxiang Tsao
  • Patent number: 8680084
    Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: March 25, 2014
    Assignee: Teva Women's Health, Inc.
    Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
  • Patent number: 8663681
    Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: March 4, 2014
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Charles E. Diliberti, Chandra Vattikonda, Sudhir R. Gorukanti, Sanjeev K. Gupta
  • Publication number: 20140030311
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: TEVA WOMEN'S HEALTH, INC.
    Inventors: Salah U. AHMED, Jiaxiang TSAO, Anu MAHASHABDE, Diane D. HARRISON
  • Patent number: 8580293
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: November 12, 2013
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • Publication number: 20130269706
    Abstract: The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b) an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.
    Type: Application
    Filed: August 18, 2011
    Publication date: October 17, 2013
    Applicant: TEVA WOMEN'S HEALTH, INC.
    Inventor: Jiaxiang Tsao
  • Patent number: 8338396
    Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: December 25, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
  • Patent number: 8323679
    Abstract: The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: December 4, 2012
    Assignee: TEVA Women's Health, Inc.
    Inventors: Salah U. Ahmed, Tahseen A. Chowdhury, Yi Luo
  • Patent number: 8288342
    Abstract: The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: October 16, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Sundeep Sethia, Kathleen Reape, Howard Hait, Carole S. Ben-Maimon
  • Publication number: 20120252767
    Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
    Type: Application
    Filed: June 8, 2012
    Publication date: October 4, 2012
    Applicant: Teva Women's Health, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
  • Patent number: 8247393
    Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 21, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Madhu Sudhan Shaik, Sanjeev K. Gupta
  • Publication number: 20120207798
    Abstract: The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in contact with a solid oral dosage form, wherein an area of contact between the handle and the solid oral dosage form forms a joint interface; (b) applying high frequency mechanical vibrations to the joint interface until the solid oral dosage form at the joint interface reaches a molten state; and (c) cooling the joint interface in a molten state to allow solidification, thereby attaching the handle to the solid oral dosage form.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 16, 2012
    Applicant: Teva Women's Health, Inc.
    Inventors: Tahseen A. CHOWDHURY, Edward J. GABRIELSKI, Christopher H. BAKER
  • Patent number: 8217024
    Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: July 10, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Madhu Sudhan Shaik, Sanjeev K. Gupta
  • Patent number: 8202534
    Abstract: The present invention relates to a method of attaching a handle to a solid oral dosage form by use of high frequency mechanical vibrations. The present invention also relates to a method of attaching a handle to a solid oral dosage form, the method comprising: (a) placing a handle in contact with a solid oral dosage form, wherein an area of contact between the handle and the solid oral dosage form forms a joint interface; (b) applying high frequency mechanical vibrations to the joint interface until the solid oral dosage form at the joint interface reaches a molten state; and (c) cooling the joint interface in a molten state to allow solidification, thereby attaching the handle to the solid oral dosage form.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: June 19, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Tahseen A. Chowdhury, Edward J. Gabrielski, Christopher H. Baker
  • Patent number: 8148560
    Abstract: The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about 1:50 to about 1:800, and wherein the vaginal tablets do not substantially change the pH of a vaginal tract.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: April 3, 2012
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Raj R. Mahajan
  • Publication number: 20110124611
    Abstract: The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
    Type: Application
    Filed: October 26, 2010
    Publication date: May 26, 2011
    Applicant: TEVA WOMEN'S HEALTH, INC.
    Inventors: ROBERT G. BELL, CAROLE S. BEN-MAIMON, BEATA ISKOLD, LANCE J. BRONNENKANT, HOWARD HAIT, KATHLEEN Z. REAPE
  • Patent number: 7908729
    Abstract: A method for attaching a handle to a tablet to form a lollipop utilizes a specific work holder. The work holder has a tooling pallet with a plurality of openings going from a top surface to a bottom surface. A bullet and a spring are located in each opening and held in place by a plate that slides through a groove in the bottom surface of the tooling pallet to block the openings in the bottom surface. Each spring is positioned between a bullet and the plate. A tablet is placed in a cavity of each bullet and a handle is placed in contact with each tablet. High frequency mechanical vibrations, such as ultrasonic vibrations, are applied to a joint interface between each tablet and bullet until the joint interface reaches a molten state. The joint interfaces are then allowed to cool, thereby attaching a handle to each tablet and forming a lollipop.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: March 22, 2011
    Assignee: Teva Women's Health, Inc.
    Inventors: Tahseen A. Chowdhury, Edward J. Gabrielski, Christopher H. Baker
  • Patent number: 7910126
    Abstract: The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: March 22, 2011
    Assignee: TEVA Women's Health, Inc.
    Inventors: Salah U. Ahmed, Tahseen A. Chowdhury, Yi Luo
  • Patent number: 7858605
    Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: December 28, 2010
    Assignee: Teva Women's Health, Inc.
    Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold